Introduction: ABO-incompatible (ABOi) living donor kidney transplantation (LDKT) is considered only for patients who do not have an ABO-compatible (ABOc) LD. Therefore, a clinically practical question is whether to proceed with ABOi LDKT or remain on dialysis while waiting for ABOc deceased donor kidney transplantation (DDKT). However, this issue has not been addressed in Asian countries, where ABOi LDKT programs are more active than DDKT programs. Methods: A total of 426 patients underwent ABOi-LDKT between 2010 and 2020 at Seoul National University Hospital and Severance Hospital, Korea. We compared outcomes between the ABOi-LDKT and the propensity-matched control groups (waiting-list-only group, n = 1,278; waiting-list-or-ABOc-DDKT group, n = 1,278). Results: The ABOi-LDKT group showed a significantly better patient survival rate than the waiting-list-only group (p = 0.001) and the waiting-list-or-ABOc-DDKT group (p = 0.048). When the ABOi-LDKT group was categorized into a high-titer group (peak anti-ABO titer ≥1:128) and a low-titer group (peak anti-ABO titer ≤1:64), the low-titer group showed better patient survival rates than those of the waiting-list-or-ABOc-DDKT group (p = 0.046) or the waiting-list-only group (p = 0.004). In contrast, the high-titer ABOi-LDKT group showed no significant benefit in patient survival compared to the waiting-list-or-ABOc-DDKT group. Death-censored graft survival in the ABOi-LDKT group was not significantly different from that in the ABOc-DDKT group (p = 0.563). Conclusion: The ABOi-LDKT group has better outcomes than the waiting-list-or-ABOc-DDKT group in a country with a long waiting time.

The number of end-stage kidney disease (ESKD) patients has been rapidly increasing, and therefore organ shortage has become an important barrier to kidney transplantation (KT). Blood group ABO-incompatible living donor KT (ABOi LDKT) is one of efforts to expand the organ pool. ABOi LDKT is considered only for patients who do not have ABO-compatible (ABOc) living donors. Therefore, a clinically practical question is whether to proceed with ABOi LDKT or remain on dialysis while waiting for ABOc deceased donor KT (DDKT). However, this issue has not been addressed in Asian countries, where ABOi LDKT programs are more active than DDKT programs. To address this question, we compared outcomes between the ABOi-LDKT and two control groups. The first control group was derived from the patients on the waitlists, some of whom received DDKT from ABOc deceased donors (waiting-list-or-ABOc-DDKT group). The second control group was derived from patients on the waitlists who had not yet undergone KT (waiting-list-only group). The ABOi-LDKT group showed a significantly better patient survival rate than the waiting-list-only group and the waiting-list-or-ABOc-DDKT group. When the ABOi-LDKT group was categorized into high- and low-titer groups according to anti-ABO antibody titer, the low-titer group showed better patient survival than those of the waiting-list-or-ABOc-DDKT group or the waiting-list-only group. In contrast, the high-titer group showed no significant benefit in patient survival compared to the waiting-list-or-ABOc-DDKT group. In conclusion, the ABOi-LDKT group has better outcomes than the waiting-list-or-ABOc-DDKT group and could be recommended to ESKD patients without ABOc donors.

1.
The Korean Society of Nephrology. Trends in epidemiologic characteristics of end-stage renal disease from 2022 KORDS (Korean Renal Data System); 2022. Available from: https://ksn.or.kr/bbs/index.php?code=report [Accessed 18 November 2022].
2.
Korea Network for Organ Sharing (KONOS). 2020 Annual data report in Korea; 2021. Available from: https://www.konos.go.kr/board/boardListPage.do?page=sub4_2_1&boardId=30 [Accessed 21 June 2021].
3.
Morath C, Zeier M, Döhler B, Opelz G, Süsal C. ABO-incompatible kidney transplantation. Front Immunol. 2017;8:234.
4.
Koo TY, Yang J. Current progress in ABO-incompatible kidney transplantation. Kidney Res Clin Pract. 2015;34(3):170–9.
5.
International registry in organ donation and transplantation: Irodat; 2021. Available from: https://www.irodat.org/img/database/pdf/Irodat%20year%202021%20_%20Final.pdf. [Accessed March 3, 2023].
6.
Kong JM, Ahn J, Park JB, Chung BH, Yang J, Kim JK, et al. ABO incompatible living donor kidney transplantation in Korea: highly uniform protocols and good medium-term outcome. Clin Transpl. 2013;27(6):875–81.
7.
Schwartz J, Stegall MD, Kremers WK, Gloor J. Complications, resource utilization, and cost of ABO-incompatible living donor kidney transplantation. Transplantation. 2006;82(2):155–63.
8.
Genberg H, Kumlien G, Wennberg L, Berg U, Tydén G. ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation. 2008;85(12):1745–54.
9.
Zschiedrich S, Jänigen B, Dimova D, Neumann A, Seidl M, Hils S, et al. One hundred ABO-incompatible kidney transplantations between 2004 and 2014: a single-centre experience. Nephrol Dial Transpl. 2016;31(4):663–71.
10.
Okumi M, Toki D, Nozaki T, Shimizu T, Shirakawa H, Omoto K, et al. ABO-incompatible living kidney transplants: evolution of outcomes and immunosuppressive management. Am J Transpl. 2016;16(3):886–96.
11.
Hamano I, Hatakeyama S, Fujita T, Murakami R, Hamaya T, Togashi K, et al. Outcome of ABO blood type-incompatible living-related donor kidney transplantation under a contemporary immunosuppression strategy in Japan. Transpl Proc. 2020;52(6):1700–4.
12.
Langhorst C, Ganner A, Schneider J, Prager EP, Walz G, Pisarski P, et al. Long-term follow-up of ABO-incompatible kidney transplantation in freiburg, Germany: a single-center outcome report. Transpl Proc. 2021;53(3):848–55.
13.
Opelz G, Morath C, Süsal C, Tran TH, Zeier M, Döhler B. Three-year outcomes following 1,420 ABO-incompatible living-donor kidney transplants performed after ABO antibody reduction: results from 101 centers. Transplantation. 2015;99(2):400–4.
14.
de Weerd AE, Betjes MGH. ABO-incompatible kidney transplant outcomes: a meta-analysis. Clin J Am Soc Nephrol. 2018;13(8):1234–43.
15.
Scurt FG, Ewert L, Mertens PR, Haller H, Schmidt BMW, Chatzikyrkou C. Clinical outcomes after ABO-incompatible renal transplantation: a systematic review and meta-analysis. Lancet. 2019;393(10185):2059–72.
16.
Massie AB, Orandi BJ, Waldram MM, Luo X, Nguyen AQ, Montgomery RA, et al. Impact of ABO-incompatible living donor kidney transplantation on patient survival. Am J Kidney Dis. 2020;76(5):616–23.
17.
Orandi BJ, Luo X, Massie AB, Garonzik-Wang JM, Lonze BE, Ahmed R, et al. Survival benefit with kidney transplants from HLA-incompatible live donors. N Engl J Med. 2016;374(10):940–50.
18.
Manook M, Koeser L, Ahmed Z, Robb M, Johnson R, Shaw O, et al. Post-listing survival for highly sensitised patients on the UK kidney transplant waiting list: a matched cohort analysis. Lancet. 2017;389(10070):727–34.
19.
Koo TY, Lee JH, Min SI, Lee Y, Kim MS, Ha J, et al. Presence of a survival benefit of HLA-incompatible living donor kidney transplantation compared to waiting or HLA-compatible deceased donor kidney transplantation with a long waiting time. Kidney Int. 2021;100(1):206–14.
20.
Song SH, Lee J, Kim BS, Kim S, Lee JG, Jeong HJ, et al. Successful launch of an ABO-incompatible kidney transplantation program to overcome the shortage of compatible living donors: experience at a single center. Clin Nephrol. 2017;88(9):117–23.
21.
Kim YC, Yu MY, Lee JP, Lee H, Min SI, Ha J, et al. The effect of desensitization therapy in kidney transplantation. Clin Exp Nephrol. 2018;22(1):179–87.
22.
Huh KH, Kim MS, Ju MK, Chang HK, Ahn HJ, Lee SH, et al. Exchange living-donor kidney transplantation: merits and limitations. Transplantation. 2008;86(3):430–5.
23.
Kim BS, Kim YS, Kim SI, Kim MS, Lee HY, Kim YL, et al. Outcome of multipair donor kidney exchange by a web-based algorithm. J Am Soc Nephrol. 2007;18(3):1000–6.
24.
Mierzejewska B, Durlik M, Lisik W, Baum C, Schroder P, Kopke J, et al. Current approaches in national kidney paired donation programs. Ann Transpl. 2013;18:112–24.
25.
Yu JH, Chung BH, Yang CW; Korean Organ Transplantation Registry Study Group. Impact of ABO incompatible kidney transplantation on living donor transplantation. PLoS One. 2017;12(3):e0173878.
26.
de Weerd AE, van den Brand J, Bouwsma H, de Vries APJ, Dooper IPMM, Sanders JSF, et al. ABO-incompatible kidney transplantation in perspective of deceased donor transplantation and induction strategies: a propensity-matched analysis. Transpl Int. 2021;34(12):2706–19.
27.
Shimmura H, Tanabe K, Ishikawa N, Tokumoto T, Takahashi K, Toma H. Role of anti-A/B antibody titers in results of ABO-incompatible kidney transplantation. Transplantation. 2000;70(9):1331–5.
28.
Stegall MD, Dean PG, Gloor JM. ABO-incompatible kidney transplantation. Transplantation. 2004;78(5):635–40.
29.
Chung BH, Lee JY, Kang SH, Sun IO, Choi SR, Park HS, et al. Comparison of clinical outcome between high and low baseline anti-ABO antibody titers in ABO-incompatible kidney transplantation. Ren Fail. 2011;33(2):150–8.
30.
Mustian MN, Cannon RM, MacLennan PA, Reed RD, Shelton BA, McWilliams DM, et al. Landscape of ABO-incompatible live donor kidney transplantation in the US. J Am Coll Surg. 2018;226(4):615–21.
31.
Heo GY, Jang Y, Choi H, Kim YC, Han SS, Kim HW, et al. Impact of ABO incompatibility and early antibody-mediated rejection on chronic antibody-mediated rejection in kidney transplant patients. J Nephrol. 2023;36(9):2571–80.
You do not currently have access to this content.